[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-001", "question": "A 28-year-old male with a history of opioid use disorder presents with syncope. He admits to taking 'massive doses' of an over-the-counter anti-diarrheal medication to manage withdrawal symptoms. ECG shows sinus bradycardia at 45 bpm, a QTc interval of 680 ms, and intermittent broad-complex beats. He is hemodynamically stable but lethargic. Magnesium sulfate 2g IV is administered without change in the rhythm. Which of the following is the most appropriate next step in management?", "options": ["Option A: IV Amiodarone infusion", "Option B: IV Isoproterenol infusion", "Option C: IV Physostigmine", "Option D: Synchronized cardioversion", "Option E: IV Calcium gluconate"], "answer": "B", "answer_index": 1, "explanation": "The patient has loperamide toxicity, which blocks cardiac sodium and potassium channels, causing QTc prolongation and wide-complex dysrhythmias. Unlike congenital Long QT (where isoproterenol is contraindicated), loperamide-induced TdP/QT prolongation is bradycardia-dependent; increasing the heart rate (chemical or electrical overdrive pacing) shortens the QT interval and prevents Torsades de Pointes. Amiodarone prolongs QT and is contraindicated.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This question describes a case of loperamide toxicity (\"massive doses\" of anti-diarrheal to manage opioid withdrawal). High doses of loperamide can cause significant cardiac toxicity, characterized by QRS widening (due to sodium channel blockade) and QTc prolongation (due to varying potassium channel blockade), often leading to Torsades de Pointes (TdP) and cardiac arrest.\n\nThe patient presents with significant bradycardia (45 bpm) and extreme QTc prolongation (680 ms). Bradycardia is a risk factor for \"pause-dependent\" TdP in the setting of acquired Long QT Syndrome. The goals of therapy are to maintain hemodynamic stability, shorten the QTc interval, and prevent malignant arrhythmias.\n\n1.  Magnesium sulfate is the first-line treatment for TdP and QT prolongation but has already been administered without effect.\n2.  Overdrive pacing is the next appropriate step for patients with drug-induced QT prolongation who have bradycardia or pause-dependent TdP. Increasing the heart rate shortens the QT interval and reduces the dispersion of repolarization, preventing R-on-T phenomena. This can be achieved electrically (transvenous pacing) or chemically. Isoproterenol is a non-selective beta-agonist generally used as a chemical pacemaker in this setting to increase the heart rate and shorten the QTc interval.\n\nAnalysis of other options:\n*   Amiodarone is a Class III antiarrhythmic that prolongs the QT interval and is contraindicated in drug-induced TdP or QT prolongation.\n*   Physostigmine is used for anticholinergic toxicity and can cause bradycardia, which would worsen this patient's condition.\n*   Synchronized cardioversion is used for unstable monomorphic VT or SVT. It is not indicated for sinus bradycardia or preventing TdP. Defibrillation (unsynchronized) would be used if the patient were in sustained pulseless TdP/VF.\n*   Calcium gluconate is used for hyperkalemia or calcium channel blocker overdose. While loperamide has some calcium channel blocking activity, the primary life-threatening mechanism described here is hERG channel blockade (QT prolongation) and sodium channel blockade. Sodium bicarbonate (not calcium) is often used for the QRS widening aspect. Isoproterenol addresses the bradycardia/QT risk more directly.\n\nThe answer is (B)\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-002", "question": "A 4-month-old female presents with failure to thrive, hypotonia, and a history of pyridoxine-responsive seizures. Laboratory evaluation reveals hypercalcemia, hypercalciuria, and a suppressed parathyroid hormone (PTH) level. Skeletal survey demonstrates diffuse demineralization and 'moth-eaten' radiolucencies at the metaphyses. Serum alkaline phosphatase (ALP) is 15 IU/L (Reference: 150-420 IU/L). Which of the following is the definitive treatment for this condition?", "options": ["Option A: High-dose Vitamin D supplementation", "Option B: Recombinant human parathyroid hormone (Teriparatide)", "Option C: Asfotase alfa", "Option D: Pyridoxine (Vitamin B6) monotherapy", "Option E: Bisphosphonate therapy"], "answer": "C", "answer_index": 2, "explanation": "The diagnosis is Hypophosphatasia (HPP), caused by a loss-of-function mutation in the ALPL gene encoding tissue-nonspecific alkaline phosphatase (TNSALP). Low ALP leads to accumulation of inorganic pyrophosphate (an inhibitor of bone mineralization) and pyridoxal-5'-phosphate (causing B6-dependent seizures due to lack of dephosphorylation). Asfotase alfa is the enzyme replacement therapy. Vitamin D and bisphosphonates are contraindicated as they may worsen hypercalcemia and inhibit mineralization further.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The clinical presentation describes a classic case of Infantile Hypophosphatasia (HPP).\n\n1.  Diagnosis: The hallmark finding is the extremely low serum alkaline phosphatase (ALP) level (15 IU/L).\n2.  Pathophysiology: HPP is caused by a loss-of-function mutation in the *ALPL* gene encoding tissue-nonspecific alkaline phosphatase (TNSALP).\n    *   Bone findings: Lack of TNSALP leads to the accumulation of inorganic pyrophosphate (PPi), a potent inhibitor of bone mineralization. This results in rickets-like skeletal changes (diffuse demineralization, \"moth-eaten\" appearances at the metaphyses), fractures, and failure to thrive.\n    *   Hypercalcemia: Due to the inability of calcium to deposit into the bone matrix, calcium remains in the circulation, causing hypercalcemia and hypercalciuria (and consequently suppressing PTH).\n    *   Seizures: TNSALP is required to dephosphorylate pyridoxal-5'-phosphate (PLP, the active form of Vitamin B6) to pyridoxal, allowing it to cross the blood-brain barrier and cell membranes. In HPP, PLP accumulates in the blood (high levels) but leads to a functional deficiency of Vitamin B6 in the brain, causing pyridoxine-responsive seizures.\n3.  Treatment:\n    *   Asfotase alfa (Option C) is a bone-targeted recombinant human TNSALP enzyme replacement therapy. It is the only FDA-approved definitive treatment for perinatal/infantile- and juvenile-onset hypophosphatasia. It improves survival, skeletal mineralization, and respiratory function.\n    *   Vitamin D (Option A) is often contraindicated because patients are already hypercalcemic.\n    *   Bisphosphonates (Option E) are chemical analogues of pyrophosphate and may further inhibit mineralization; they are generally contraindicated.\n    *   Pyridoxine (Option D) is used to manage the seizures, but it does not treat the underlying enzyme deficiency or the skeletal complications.\n\nThe answer is (C)\n\nQuestion: A 4-month-old female presents with failure to thrive, hypotonia, and a history of pyridoxine-responsive seizures. Laboratory evaluation reveals hypercalcemia, hypercalciuria, and a suppressed parathyroid hormone (PTH) level. Skeletal survey demonstrates diffuse demineralization and 'moth-eaten' radiolucencies at the metaphyses. Serum alkaline phosphatase (ALP) is 15 IU/L (Reference: 150-420 IU/L). Which of the following is the definitive treatment for this condition?\nOptions:\nA. Option A: High-dose Vitamin D supplementation\nB. Option B: Recombinant human parathyroid hormone (Teriparatide)\nC. Option C: Asfotase alfa\nD. Option D: Pyridoxine (Vitamin B6) monotherapy\nE. Option E: Bisphosphonate therapy\nPick the single best answer.\nOutput MUST end with: The answer is (X)\nUse only one capital letter (A, B, C, D, E).\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-003", "question": "A 68-year-old male presents with recurrent fevers, painful auricular chondritis, pulmonary infiltrates, and macrocytic anemia. He has been treated for 'refractory relapsing polychondritis' without success. Bone marrow biopsy reveals hypercellularity with prominent cytoplasmic vacuoles in myeloid and erythroid precursor cells. Which of the following is the most likely diagnosis?", "options": ["Option A: Myelodysplastic Syndrome (MDS) with excess blasts", "Option B: VEXAS syndrome", "Option C: Sweet syndrome", "Option D: Polyarteritis Nodosa", "Option E: Granulomatosis with Polyangiitis"], "answer": "B", "answer_index": 1, "explanation": "VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a recently described disorder caused by somatic mutations in the UBA1 gene. It presents in older men with inflammatory features (chondritis, vasculitis, fevers) and hematologic abnormalities (macrocytic anemia). The pathognomonic finding is vacuoles in myeloid and erythroid precursors in the bone marrow.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient presents with a constellation of systemic inflammatory symptoms (fevers, chondritis, pulmonary infiltrates) and hematologic abnormalities (macrocytic anemia, hypercellular marrow). The key diagnostic clues are:\n1.  Demographics: Older male.\n2.  Clinical phenotype: Features masquerading as refractory rheumatic diseases, specifically relapsing polychondritis (auricular chondritis).\n3.  Hematopathology: Macrocytic anemia and the specific finding of prominent cytoplasmic vacuoles in myeloid and erythroid precursor cells in the bone marrow.\n\nThis presentation is characteristic of VEXAS syndrome (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic). VEXAS syndrome is caused by somatic mutations in the *UBA1* gene on the X chromosome. It affects primarily older men and connects features of myelodysplastic syndromes (macrocytic anemia, vacuolization) with severe inflammatory conditions (chondritis, vasculitis, neutrophilic dermatoses). Patients are frequently misdiagnosed with conditions like relapsing polychondritis, polyarteritis nodosa, or Sweet syndrome before the correct diagnosis is made identifying the *UBA1* mutation and characteristic marrow vacuoles.\n\nSweet syndrome (C), Polyarteritis Nodosa (D), and Granulomatosis with Polyangiitis (E) are inflammatory conditions that can share overlapping symptoms with VEXAS, but they do not explain the specific bone marrow vacuolization coupled with the distinct hematologic presentation. While MDS (A) involves marrow abnormalities, the specific vacuolization pattern in the context of this specific inflammatory profile defines VEXAS syndrome.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-004", "question": "A 55-year-old female with chronic malnutrition and a history of chronic acetaminophen use for osteoarthritis presents with altered mental status. Arterial blood gas shows pH 7.28, pCO2 28 mmHg, HCO3 12 mEq/L. The anion gap is 24. Lactate is 0.9 mmol/L, serum ketones are negative, and creatinine is 1.1 mg/dL. Toxic alcohol screen is negative. Which of the following is the most appropriate therapeutic intervention?", "options": ["Option A: IV Fomepizole", "Option B: IV Sodium Bicarbonate", "Option C: N-acetylcysteine", "Option D: Hemodialysis", "Option E: Thiamine and Dextrose"], "answer": "C", "answer_index": 2, "explanation": "This patient has high anion gap metabolic acidosis due to 5-oxoproline (pyroglutamic acid) accumulation. This occurs in the setting of glutathione depletion (malnutrition, acetaminophen use), which disrupts the gamma-glutamyl cycle. N-acetylcysteine replenishes glutathione stores, restoring the feedback loop and halting 5-oxoproline production. Fomepizole is for toxic alcohols, which were ruled out.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The clinical presentation is characteristic of pyroglutamic acidosis (5-oxoprolinemia). This condition presents as a high anion gap metabolic acidosis (HAGMA) with altered mental status.\n\n1.  Analysis of the Acid-Base Status:\n    *   pH 7.28 (Acidemia)\n    *   HCO3 12 (Metabolic Acidosis)\n    *   Anion Gap = 24 (High Anion Gap)\n    *   Therefore, the patient has a HAGMA.\n\n2.  Differential Diagnosis (MUDPILES/GOLD MARK):\n    *   Methanol / Toxic Alcohols: Screen is negative (rules out Option A).\n    *   Uremia: Creatinine is 1.1 mg/dL, ruling out renal failure as the primary cause (rules out need for dialysis for uremia, Option D).\n    *   DKA / Ketoacidosis / Starvation: Serum ketones are negative (rules out Option E as primary treatment for alcoholic/starvation ketoacidosis).\n    *   Lactic Acidosis: Normal (0.9 mmol/L).\n    *   Salicylates: No history provided, though chronic aspirin use is possible, the history points strongly to something else.\n    *   Pyroglutamic Acid / Acetaminophen: This diagnosis fits strictly by exclusion and history.\n\n3.  Pathophysiology:\n    *   Pyroglutamic acidosis occurs in patients with glutathione depletion.\n    *   Risk factors include: Chronic acetaminophen use (acetaminophen consumes glutathione), malnutrition (decreased supply of glutathione precursors), female gender, and renal insufficiency (though not strictly required).\n    *   Mechanism: Glutathione depletion leads to loss of feedback inhibition on the enzyme $\\gamma$-glutamylcysteine synthetase. This increases the production of $\\gamma$-glutamylcysteine, which is partially converted into 5-oxoproline (pyroglutamic acid) rather than glutathione. The accumulation of this organic acid causes the HAGMA.\n\n4.  Treatment:\n    *   The definitive treatment aims to restore glutathione levels to re-establish feedback inhibition and stop the production of pyroglutamic acid.\n    *   N-acetylcysteine (NAC) is the glutathione precursor of choice.\n    *   The offending agent (acetaminophen) should be discontinued.\n\nOption Analysis:\n*   Option A: Fomepizole is the antidote for methanol or ethylene glycol poisoning. The screen is negative.\n*   Option B: Bicarbonate is generally reserved for severe acidemia (pH < 7.1) or specific toxidromes (salicylates/TCAs). It does not treat the underlying cause.\n*   Option C: NAC replenishes glutathione stores, treating the root cause of the pyroglutamic acidosis.\n*   Option D: Dialysis is reserved for refractory acidosis or removal of dialyzable toxins (like toxic alcohols or salicylates) in severe cases. The patient's creatinine is normal, and the acidosis is likely reversible with NAC.\n*   Option E: While thiamine is appropriate for a malnourished patient to prevent Wernicke's, it does not treat the specific metabolic acidosis present (AG 24 with no ketones).\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-005", "question": "A 32-year-old female presents with amenorrhea and galactorrhea. MRI reveals a 4.5 cm pituitary macroadenoma with invasion into the cavernous sinus. Visual fields are intact. Serum prolactin is reported as 145 ng/mL (Reference: <25 ng/mL). Which of the following is the most appropriate next step in management?", "options": ["Option A: Referral for transsphenoidal resection", "Option B: Stereotactic radiosurgery", "Option C: Measurement of prolactin in diluted serum", "Option D: Octreotide scintigraphy", "Option E: Bilateral inferior petrosal sinus sampling"], "answer": "C", "answer_index": 2, "explanation": "A 4.5 cm prolactinoma should typically produce prolactin levels >1,000-10,000 ng/mL. A mildly elevated level in the setting of a giant adenoma suggests the 'Hook Effect,' where excessive antigen saturates the assay antibodies, preventing sandwich formation and leading to a falsely low result. Diluting the sample (1:100) reveals the true elevated value. Confirming a prolactinoma is crucial because dopamine agonists (cabergoline) are the first-line treatment, not surgery.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The clinical presentation involves a very large pituitary tumor (4.5 cm macroadenoma) and a moderately elevated serum prolactin level (145 ng/mL).\n\nThere is a significant discordance between the tumor size and the prolactin level. Typically, prolactinomas produce prolactin in proportion to their size (roughly correlation is >200 ng/mL for macroadenomas, and a 4.5 cm tumor would typically result in levels >1,000 ng/mL or even >10,000 ng/mL).\n\nA level of 145 ng/mL in the presence of a macroadenoma usually suggests the \"stalk effect,\" where a non-functioning adenoma compresses the pituitary stalk, interfering with dopamine delivery (which normally inhibits prolactin release).\n\nHowever, with such a large tumor, one must rule out the \"Hook Effect\" (high-dose antigen hook effect). This is an immunoradiometric assay artifact where extremely high levels of prolactin saturate the signaling antibodies, preventing the formation of the antibody-antigen \"sandwich\" and leading to falsely low reported levels. If this is a giant prolactinoma, the treatment is medical (dopamine agonists like cabergoline), which causes rapid tumor shrinkage. If it is a non-functioning adenoma, the primary treatment is often surgical resection.\n\nTo distinguish between these two very different management pathways, the laboratory must repeat the prolactin measurement using a diluted serum sample. If the prolactin level increases significantly upon dilution, the diagnosis is a giant prolactinoma (Hook Effect confirmed). If it drops proportionally, the diagnosis is likely a non-functioning adenoma with the stalk effect.\n\nStep-by-step reasoning for the options:\n*   Option A: Referral for transsphenoidal resection is premature. If this is a giant prolactinoma, surgery is not the first-line treatment; dopamine agonists are effective and safer.\n*   Option B: Radiosurgery is a third-line treatment for refractory cases.\n*   Option C: Measurement of prolactin in diluted serum is the necessary diagnostic step to rule out the hook effect and determine the correct diagnosis and subsequent treatment.\n*   Option D: Octreotide scintigraphy is used for somatotroph (GH) or neuroendocrine tumors, not typically for prolactinomas.\n*   Option E: IPSS is used to differentiate pituitary from ectopic sources of ACTH in Cushing syndrome.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-006", "question": "A 60-year-old male with a history of radiation therapy for Hodgkin lymphoma presents with signs of cardiac tamponade. Pericardiocentesis is performed, draining 800 mL of bloody fluid. Following drainage, the intrapericardial pressure drops to 0 mmHg, but the right atrial pressure remains elevated at 18 mmHg with a prominent y-descent that was previously absent. Which of the following is the most likely diagnosis?", "options": ["Option A: Incomplete drainage of the effusion", "Option B: Effusive-constrictive pericarditis", "Option C: Right ventricular infarction", "Option D: Pulmonary embolism", "Option E: Flash pulmonary edema"], "answer": "B", "answer_index": 1, "explanation": "Effusive-constrictive pericarditis is characterized by concurrent tamponade and constriction. The visceral pericardium is thickened and constrictive. Initially, the effusion masks the constriction (tamponade physiology: blunted y-descent). After drainage, the tamponade resolves, but the underlying constriction becomes manifest (elevated RA pressure with prominent y-descent). Treatment requires visceral pericardiectomy.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This scenario describes a classic presentation of effusive-constrictive pericarditis.\n\nHere is the step-by-step breakdown:\n1.  Risk Factor: The patient has a history of radiation therapy for Hodgkin lymphoma, which is a known cause of pericardial disease, including fibrosis and constriction.\n2.  Initial Presentation (Effusive component): The patient presents with cardiac tamponade, characterized by fluid accumulation compressing the heart. In pure tamponade, right atrial pressure (RAP) is elevated, and the y-descent is typically blunted or absent because the fluid prevents rapid early diastolic filling.\n3.  Intervention: Pericardiocentesis is performed, successfully draining the fluid (evidenced by the drop in intrapericardial pressure to 0 mmHg).\n4.  Post-Intervention Hemodynamics (Constrictive component): despite the removal of the fluid, the right atrial pressure remains elevated (18 mmHg). Furthermore, a prominent y-descent appears. A prominent, rapid y-descent (\"dip and plateau\" or square root sign in the ventricle) is a hallmark of constrictive pericarditis, representing rapid early diastolic filling that is abruptly halted by a stiff, non-compliant visceral pericardium.\n\nIn effusive-constrictive pericarditis, the pathology is located in the visceral pericardium. Initially, the effusion causes tamponade physiology. Once the fluid is removed, the underlying stiff visceral pericardium continues to constrict the heart, preventing the RAP from normalizing and unmasking the signs of constriction (prominent y-descent). This distinguishes it from incomplete drainage (where intrapericardial pressure would remain elevated) and pure tamponade (which resolves with drainage).\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-007", "question": "A 65-year-old male is admitted to the ICU for sedation and mechanical ventilation. On day 3 of a continuous propofol infusion, he develops new Right Bundle Branch Block with coved ST-segment elevation in leads V1-V3. Labs reveal severe metabolic acidosis (pH 7.18), Lactate 9 mmol/L, and CK 8,000 U/L. Echocardiogram shows new global hypokinesis. Which of the following is the most likely diagnosis?", "options": ["Option A: Acute Anterior ST-Elevation MI", "Option B: Massive Pulmonary Embolism", "Option C: Propofol Infusion Syndrome", "Option D: Brugada Syndrome unmasked by fever", "Option E: Septic Cardiomyopathy"], "answer": "C", "answer_index": 2, "explanation": "Propofol Infusion Syndrome (PRIS) is a rare but lethal complication of high-dose/long-duration propofol. It causes mitochondrial failure leading to rhabdomyolysis, metabolic acidosis, heart failure, and characteristic ECG changes (often Brugada-like pattern: RBBB with coved ST elevation). Immediate cessation of propofol and supportive care is required.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This clinical scenario presents a patient with classic features of Propofol Infusion Syndrome (PRIS). PRIS is a rare but life-threatening complication of propofol administration, typically associated with high-dose infusions (>4 mg/kg/hr) for prolonged periods (>48 hours), although it can occur with lower doses or shorter durations.\n\nThe key features presented in this case match the diagnostic criteria for PRIS:\n1.  Context: The patient has been on a continuous propofol infusion for 3 days.\n2.  Metabolic Derangement: Severe metabolic acidosis (pH 7.18) and elevated lactate (9 mmol/L). Acidosis is often an early sign.\n3.  Rhabdomyolysis: Significantly elevated Creatine Kinase (8,000 U/L) indicates muscle breakdown, a hallmark of PRIS.\n4.  Cardiac Failure: New global hypokinesis on echocardiogram indicates acute cardiac failure.\n5.  ECG Changes: The development of Right Bundle Branch Block (RBBB) with coved ST-segment elevation in leads V1-V3 describes a Type 1 Brugada-like pattern. This specific ECG pattern is a known electrical manifestation of PRIS (Brugada phenocopy) and is an ominous sign of impending fatal arrhythmia.\n\nWhile an anterior MI (Option A) could cause ST changes and shock, the specific \"coved\" description, combined with severe rhabdomyolysis and the context of propofol use, strongly favors localizing the pathology to the drug toxicity. Neither Pulmonary Embolism (Option B) nor Sepsis (Option E) typically presents with this specific constellation of rhabdomyolysis and Brugada-pattern ECG changes. While fever can unmask congenital Brugada syndrome (Option D), that condition implies a primary electrical issue without the associated multi-organ metabolic collapse (rhabdomyolysis, profound acidosis, pump failure) seen here, which are caused by mitochondrial inhibition from propofol.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-008", "question": "A 58-year-old male with dyslipidemia develops proximal muscle weakness and myalgias. His CK is 8,500 U/L. Atorvastatin is discontinued. Two months later, his weakness has progressed, and CK remains elevated at 9,200 U/L. Muscle biopsy shows necrotizing myopathy with minimal inflammation. Testing for anti-HMGCR antibodies is positive. Which of the following is the most appropriate management?", "options": ["Option A: Switch to Rosuvastatin", "Option B: Initiate Coenzyme Q10 supplementation", "Option C: Initiate IVIG and/or systemic immunosuppression", "Option D: Observation for spontaneous resolution", "Option E: Dantrolene sodium"], "answer": "C", "answer_index": 2, "explanation": "This patient has Statin-Associated Autoimmune Myopathy (SAAM), specifically anti-HMGCR positive necrotizing myopathy. Unlike self-limited statin myotoxicity, this is an autoimmune process that progresses despite statin cessation. It requires aggressive immunosuppression (steroids, IVIG, Rituximab, or Methotrexate) to prevent permanent muscle loss.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The clinical presentation described is classic for Statin-Associated Autoimmune Myopathy (also known as anti-HMGCR myopathy), a form of Immune-Mediated Necrotizing Myopathy (IMNM). Key features distinguishing this from benign statin-induced myalgia or toxic myopathy include:\n1.  Persistence and Progression: The weakness and CK elevation continued and worsened ($9,200$ U/L) months after stopping the statin.\n2.  Biopsy Findings: Necrotizing myopathgy with minimal inflammation is the hallmark distinct from polymyositis or dermatomyositis (which show significant inflammation).\n3.  Serology: Positive anti-HMGCR antibodies confirm the diagnosis.\n\nManagement Analysis:\n*   Option A: Re-challenging with another statin (Rosuvastatin) is contraindicated as it will exacerbate the autoimmune response against the HMG-CoA reductase enzyme.\n*   Option B: Coenzyme Q10 is sometimes used for benign statin myalgias but does not address the autoimmune pathophysiology of this condition.\n*   Option C: Because this is an autoimmune condition that does not resolve spontaneously upon statin cessation, aggressive immunosuppressive therapy is required. Standard treatment includes corticosteroids combined with steroid-sparing agents (e.g., methotrexate, azathioprine, mycophenolate) or IVIG. IVIG can be particularly effective in anti-HMGCR myopathy.\n*   Option D: Observation is inappropriate because the disease is progressive and can lead to severe, permanent muscle weakness/atrophy.\n*   Option E: Dantrolene is the antidote for malignant hyperthermia, not autoimmune myopathy.\n\nTherefore, the most appropriate management is to initiate immunosuppressive therapy.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-009", "question": "A 2-week-old XX infant presents with ambiguous genitalia (virilization). Vital signs reveal a blood pressure of 96/60 mmHg (hypertensive for age). Laboratory evaluation shows Sodium 136 mEq/L and Potassium 2.9 mEq/L. 17-hydroxyprogesterone is elevated. Which of the following enzyme deficiencies is the most likely cause?", "options": ["Option A: 21-hydroxylase deficiency", "Option B: 11-beta-hydroxylase deficiency", "Option C: 17-alpha-hydroxylase deficiency", "Option D: 3-beta-hydroxysteroid dehydrogenase deficiency", "Option E: P450 oxidoreductase deficiency"], "answer": "B", "answer_index": 1, "explanation": "Congenital Adrenal Hyperplasia due to 11-beta-hydroxylase deficiency blocks cortisol synthesis, shunting precursors to androgens (causing virilization in females) and accumulating 11-deoxycorticosterone (DOC). DOC is a potent mineralocorticoid, leading to salt retention, hypertension, and hypokalemia. This distinguishes it from the more common 21-hydroxylase deficiency, which causes salt-wasting (hypotension, hyperkalemia).", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This question describes a clinical presentation characteristic of a specific form of Congenital Adrenal Hyperplasia (CAH). Let's break down the findings:\n\n1.  XX Infant with Ambiguous Genitalia (Virilization): This indicates prenatal exposure to excessive androgens. This narrows the differential to enzyme deficiencies that shunt precursors toward the androgen pathway (e.g., 21-hydroxylase deficiency, 11-beta-hydroxylase deficiency). It rules out 17-alpha-hydroxylase deficiency, which prevents androgen synthesis and would cause normal female external genitalia in an XX infant (or undervirilization in XY).\n2.  Hypertension and Hypokalemia: The blood pressure of 96/60 mmHg is high for a 2-week-old, and potassium is low (2.9 mEq/L). These findings suggest mineralocorticoid excess (salt retention).\n3.  Elevated 17-hydroxyprogesterone: While classically associated with 21-hydroxylase deficiency, levels are often elevated in 11-beta-hydroxylase deficiency as well.\n\nAnalysis of Options:\n\n*   A. 21-hydroxylase deficiency: This is the most common cause of CAH. While it causes virilization and elevated 17-OHP, severe forms result in salt-wasting (low sodium, high potassium) and hypotension due to a lack of aldosterone. This contradicts the patient's hypertension and hypokalemia.\n*   B. 11-beta-hydroxylase deficiency: This enzyme deficiency impairs the conversion of 11-deoxycorticosterone (DOC) to corticosterone (and eventually aldosterone) and 11-deoxycortisol to cortisol. The accumulation of DOC, a potent mineralocorticoid, leads to sodium retention, volume expansion, hypertension, and hypokalemia. The block also shunts precursors toward androgen synthesis, causing virilization in XX females. This profile matches the patient perfectly.\n*   C. 17-alpha-hydroxylase deficiency: This causes hypertension and hypokalemia due to mineralocorticoid excess, but it impairs androgen synthesis. Therefore, an XX infant would not have virilized (ambiguous) genitalia.\n*   D. 3-beta-hydroxysteroid dehydrogenase deficiency: This typically presents with salt-wasting (hypotension, hyperkalemia) and DHEA accumulation. It does not fit the electrolyte or blood pressure profile.\n*   E. P450 oxidoreductase deficiency: This presents with characteristic skeletal malformations (Antley-Bixler syndrome) and complex steroid abnormalities, usually not the classic hypertension/virilization picture described here.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-010", "question": "A 45-year-old male on chronic amiodarone therapy for atrial fibrillation presents with weight loss and palpitations. TSH is <0.01 mIU/L and Free T4 is elevated. He has no neck pain. Thyroid ultrasound with color flow Doppler reveals an absence of vascularity within the thyroid parenchyma. Which of the following is the most appropriate initial treatment?", "options": ["Option A: Methimazole", "Option B: Propylthiouracil", "Option C: Prednisone", "Option D: Radioactive Iodine ablation", "Option E: Potassium Perchlorate"], "answer": "C", "answer_index": 2, "explanation": "This is Type 2 Amiodarone-Induced Thyrotoxicosis (AIT), which is a destructive thyroiditis caused by direct cytotoxic effects of the drug. The key differentiator from Type 1 AIT (Jod-Basedow/iodine-induced synthesis) is the Doppler flow: Type 1 has increased vascularity, while Type 2 has absent vascularity. Type 2 is treated with high-dose glucocorticoids. Thionamides (Methimazole) are ineffective for destructive thyroiditis.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Here is the step-by-step reasoning for the chosen answer:\n\n1.  Diagnosis: The patient presents with thyrotoxicosis (suppressed TSH, elevated Free T4) in the setting of chronic amiodarone therapy. This is Amiodarone-Induced Thyrotoxicosis (AIT).\n\n2.  Classification of AIT: There are two main types of AIT, managed differently.\n    *   Type 1 AIT: Occurs in patients with underlying thyroid pathology (e.g., latent Graves' disease or multinodular goiter). It is caused by increased thyroid hormone synthesis due to the high iodine load (Jod-Basedow phenomenon). On color flow Doppler ultrasound, the thyroid parenchyma typically shows increased vascularity.\n    *   Type 2 AIT: Occurs in patients with a previously normal thyroid gland. It is a destructive thyroiditis caused by the direct cytotoxic effect of amiodarone on thyroid follicular cells, leading to the release of preformed hormone. On color flow Doppler ultrasound, the thyroid parenchyma shows absent or decreased vascularity.\n\n3.  Application to the Patient: The clinical vignette specifies that the thyroid ultrasound with color flow Doppler reveals an absence of vascularity. This finding is the hallmark of Type 2 AIT (destructive thyroiditis).\n\n4.  Treatment Selection:\n    *   Type 1 AIT is treated with antithyroid medications (thionamides) like Methimazole (Option A) or Propylthiouracil (Option B) to block hormone synthesis. Potassium Perchlorate (Option E) can be used to block iodine uptake but is not the primary treatment for Type 2.\n    *   Type 2 AIT is an inflammatory, destructive process. Therefore, the treatment of choice is high-dose glucocorticoids, such as Prednisone (Option C), to reduce inflammation and halt the destruction of thyroid cells.\n    *   Radioactive Iodine ablation (Option D) is generally not effective in AIT because the thyroid gland is saturated with iodine from the amiodarone, resulting in very low uptake of the radioactive isotope.\n\n5.  Conclusion: Since the patient has Type 2 AIT based on the Doppler findings, Prednisone is the most appropriate initial treatment.\n\nThe answer is (C)"}]